Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Reduced by Community Bank & Trust Waco Texas

Community Bank & Trust Waco Texas lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,320 shares of the medical research company’s stock after selling 144 shares during the period. Community Bank & Trust Waco Texas’ holdings in Thermo Fisher Scientific were worth $701,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Monument Group Wealth Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $425,000. Marks Group Wealth Management Inc increased its holdings in Thermo Fisher Scientific by 6.0% in the fourth quarter. Marks Group Wealth Management Inc now owns 8,857 shares of the medical research company’s stock worth $4,701,000 after buying an additional 504 shares during the last quarter. National Wealth Management Group LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $238,000. Larson Financial Group LLC lifted its position in Thermo Fisher Scientific by 21.1% during the 4th quarter. Larson Financial Group LLC now owns 5,025 shares of the medical research company’s stock valued at $2,667,000 after purchasing an additional 875 shares during the period. Finally, 1900 Wealth Management LLC boosted its stake in Thermo Fisher Scientific by 3.2% in the fourth quarter. 1900 Wealth Management LLC now owns 1,294 shares of the medical research company’s stock valued at $687,000 after acquiring an additional 40 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.5 %

NYSE:TMO traded down $2.60 during mid-day trading on Wednesday, hitting $571.99. 817,016 shares of the company’s stock were exchanged, compared to its average volume of 1,552,031. The firm has a market capitalization of $218.33 billion, a P/E ratio of 37.22, a PEG ratio of 2.31 and a beta of 0.80. The company has a 50 day simple moving average of $572.03 and a 200-day simple moving average of $528.72. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period in the previous year, the business earned $5.40 EPS. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TMO. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. HSBC lifted their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Citigroup began coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Finally, Raymond James upped their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $604.69.

Insider Transactions at Thermo Fisher Scientific

In related news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock valued at $28,513,384 in the last quarter. 0.32% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.